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Abstract. Background: No consensus exists regarding
further therapy for the management of hormone-refractory
prostate cancer. In this phase II study, the combination of
Vinorelbine with 5-Fluorouracil and folinic acid (FLN
regimen) was evaluated in patients with progressive or
resistant disease after hormone therapy. Patients and
Methods: Thirty-four patients were treated with Vinorelbine
at a dose of 20 mg/m2 intravenously (i.v.) on days 1 and 3,
folinic acid (FA), 100 mg/m2 i.v. and 5-Fluorouracil (5-FU),
350 mg/m2 i.v. as a short infusion on days 1 to 3. The therapy
was given in an out-patient setting, every 3 weeks. Results: All
of the 34 eligible patients were evaluable for toxicity and 30
for activity. A total of 127 cycles was administered (91% at
full dose). Among the15 patients with measurable disease,
four had a partial response (26.6%; C.I. 95%, 28.3% to
65.7%) and four achieved stable disease. In 14 patients
(47%) a clinical benefit was documented. Six out of 15
patients with bone-only involvement had stable disease
(40%). The median duration of stabilization and partial
response was 16 weeks (range 4-24 weeks). The most
common toxicity was hematological: Grade 4 (NCI-CTC
scale) in five patients at re-cycle. Other toxicities were of low
incidence and easy to manage. Conclusion: The encouraging
results obtained with the FLN regimen in terms of clinical
benefit and its predictable and manageable toxicity support
the palliative role of this chemotherapeutic strategy in
hormone-refractory prostate patients.
Androgen-ablation therapy, either through bilateral
orchiectomy or the administration of luteinizing hormone-
releasing hormone agonists, associated or not with anti-
androgens, has been a mainstay of treatment for advanced
prostate cancer. Although most patients respond to
androgen ablation as an initial systemic therapy, the median
duration of response is no longer than 12-18 months (1).
Nearly all patients will develop hormone-independent
disease and, once the disease becomes hormone-refractory,
the median survival ranges from 6 to 12 months (2). Anti-
androgen withdrawal may induce a brief clinical response in
about 30% of patients (3), but there is no consensus
regarding the most appropriate second-line treatment to be
given in patients with "hormone-refractory" disease. Despite
the "recognized poor chemo-sensitivity" of prostate cancer, a
number of single agents have been identified that have
potential benefit in men with metastatic hormone-refractory
disease.
Various single drugs such, as antimetabolities, alkylating
agents, vinca alkaloids, nitrosoureas and combinations of
drugs have shown little or no activity in inducing tumor
regression, a drop of serum prostate specific antigen (PSA)
levels and reduction of the pain score, but have failed to
have a significant impact on survival. Recent studies
demonstrated an impact on overall survival in patients
treated with docetaxel (4, 5). 
The response to chemotherapy treatment is conventionally
measured by changes in the size of measurable bi-dimensional
soft tissue lesions. Such lesions occur infrequently in patients
with metastatic prostate cancer because of bone-only disease
and, therefore, the conventional criteria for tumor response
are not useful for phase II studies in this setting of patients.
The change in the PSA level as a measure of response to
chemotherapy is controversial, but has been used as a
surrogate marker of response (6, 7).
In a population of elderly patients, symptom palliation
should be the primary end-point of therapy with the aim of
delaying the onset and/or progression of symptoms. Recently,
studies emphasizing the "clinical benefit" as a principal end-
point of antitumor treatment in advanced prostate cancer
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have shown that chemotherapy can result in an improved
quality of life in advanced prostate cancer (7, 8). 
Vinorelbine is a semi-synthetic vinca alkaloid that has a
cytotoxic effect on a wide range of tumor cell lines (9). It is
a mitotic inhibitor with a higher therapeutic index and less
neurotoxicity than other vinca alkaloids, related to the lower
degree of damage to axonal microtubules (10). The dose-
limiting toxicity of vinorelbine is granulocytopenia (11).
The experience in prostate cancer with Vinorelbine is
limited. Several phase II studies have shown promising
results in terms of clinical response and reduction of
analgesic consumption in patients with hormone-
independent disease. These trials have demonstrated clinical
benefit responses of 20-40% and 20% PSA-value reduction
when used as single agent (12-16). The impressive
effectiveness observed with Vinorelbine as a single agent
and its favorable toxicity profile has led to its testing in
combination with other cytotoxics in advanced prostate
cancer.
The combination with other vinca alkaloids, etoposide
and/or estramustine was shown to yield remissions in about
30-40%, with prolonged stable disease and manageable
toxicity (17-19). 5-Fluorouracil in patients with hormone-
independent disease, modulated by folinic acid or combined
with cisplatin or interferons, also demonstrated clinical
activity with a relativly good tolerability (20-22).
The results of a combination of Vinorelbine with 
5-Fluorouracil (5-FU) and folinic acid (FA) (FLN regimen)
were evaluated in 34 patients with progressive hormone-
refractory prostate cancer (HRPC).
Patients and Methods
Patients. Patients were eligible if they had histologically-confirmed
adenocarcinoma of the prostate, age <80 years, ECOG
performance status (PS) ≤3, adequate bone marrow reserve
defined by granulocyte count ≥1,500 x 109/l, hemoglobin 
>9.0 mg/dl, platelet count >100x109/l, adequate hepatic (bilirubin
≤2.0 mg/dl, AST≤3 the upper limit of normal except for liver
involvement) and normal renal function (creatinine within the
normal ranges) and an estimated life expectancy ≥12 weeks.
Patients with central nervous system involvement, peripheral
neuropathy or unstable conditions, such as cardiovascular disease
(myocardial infarction or active angina within 12 months before the
study entry) were excluded. 
Pain had to be stable during the last week before study entry.
Patients with measurable or unmeasurable disease were included
in the study. Informed consent was obtained before entry. 
Pre-treatment evaluation and follow-up studies. Pre-treatment
evaluation included a complete medical history, clinical
examination, blood cell count, serum biochemistry profile, serum
PSA, ECG, chest X-ray, computerized tomography of the abdomen
and pelvis, radionuclide bone scan and X-ray details of pathological
spots. Clinical monitoring was performed once weekly with a
complete blood count.
Serum chemistries and serum PSA measurements were assessed
every cycle. In patients with measurable disease, antitumor activity
was evaluated every three courses (i.e., 9 weeks) on all measurable
sites and all of the patients were scheduled for at least two cycles
in order to be eligible for assessment of tumor response. In
patients with tumor responses or stable disease, the treatment was
continued to a maximum of 8 cycles. In the event of suspicious
progressive disease, due to a deterioration of the PS or a
significant increase in values of PSA, disease sites were evaluated
after two courses. 
In patients with unmeasurable disease, treatment evaluation was
performed with PSA monitoring at every cycle and with bone scan
at the end of the sixth course.
Toxicity was graded according to NCI-CTC criteria (23).
Patients were considered evaluable for toxicity if they received at
least one cycle of chemotherapy. The response to therapy was
mainly assessed on serial measurements of serum PSA levels. For
documenting PSA response, a decrease ≥50% of baseline values
in two consecutive measurements at a 3-week interval was
required; if the marker increased >50% in two consecutive assays,
progressive status was defined. Patients without deterioration of
performance status, who did not meet the PSA criteria for
progression, were considered to have stable disease.
In patients with measurable disease, tumor response was
defined according to the WHO criteria (24). A complete remission
(CR) required the complete disappearance of all disease as
observed on a CT scan. A partial remission (PR) denoted a
greater than 50% reduction in the sum of the products of the
greatest perpendicular diameters of all tumor nodules by CT scan.
A reduction or a progression less than 25% was considered to be
stable disease (SD).
In the case of bone metastases concomitant to measurable sites:
PR or SD were reported if PR or SD in measurable lesions was
associated with PR or SD in PSA levels without bone pain
progression. Pain was treated according to the WHO guidelines (25).
They represent a sequential guideline, based on a 3-step approach.
In the first step, patients with slight pain receive NSAIDs as the
main analgesics; in the second step, weak opioids are added, for
moderate pain. If severe pain is still present, weak opioids are
substituted with strong opioids, namely morphine. This approach
appears able to control the vast majority of painful cancer-related
conditions (26).
Bone pain was evaluated according to analgesic consumption.
Patients were divided into three groups, depending on the kind of
drug used. The first group included patients requiring NSAIDs for
satisfactory pain control (e.g., Visual Analog Scale-VAS less than
4); in the second group were included those patients requiring
weak opioids, namely tramadol or codeine, while the third group
was comprised of patients requiring strong opioids, namely oral or
parenteral morphine, oral methadone or transdermal fentanyl. The
percentage of patients at each step and of those switching from one
step to another were also registered. This evaluation approach
closely follows the WHO guidelines for cancer pain control (25).
The clinical benefit response was defined by continued
improvement in one category from the baseline ECOG PS for a
minimum of 8 weeks or reduction of NSAIDs or analgesic
consumption by an inverse step approach.
Statistical analysis. The primary objective of this phase II study
was the assessment of the clinical benefit; secondary end-points
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were the evaluation of antitumor activity, measured as overall
response rate, response duration, time to progression, overall
survival and toxicity.
Time-to-event end-points were estimated using the method of
Kaplan and Meier (27). The duration of response was measured
from the first documentation of response to the date of disease
progression, for responders only. Progression-free survival was
measured from the first day of treatment to the date of disease
progression or death, whichever occurred first, for all registered
patients. The overall survival was measured from the first day of
treatment to the date of death, for all included patients.
Simon's two-stage optimal design was used for patient accrual
(28). The regimen would be considered promising if a clinical
benefit was obtained in at least 30% of the patients, but would be
regarded unworthy if a clinical benefit was measured in less than
10% of the patients. The first stage was planned to accrue ten
patients, with a second stage accruing an additional 19 patients if at
least one patient achieved a clinical benefit in the first stage. The
treatment would be considered active if at least six out of 29
patients responded. This design yields a probability of, at most,
0.05 of accepting a treatment as active whose true response rate
was less than 10%, and a probability of, at most, 0.2 of rejecting a
treatment whose true response rate was more than 30%.
Treatment plan. The treatment consisted of a fixed dose of 100 mg/m2
FA administered by injection into a running i.v. infusion of dextrose
5% or normal saline over a period of 10 min on days 1 to 3, followed
by 5-FU at a dose of 350 mg/m2 administered by means of a 15-min
i.v. infusion on days 1, 2 and 3. Vinorelbine was administered at 
20 mg/m2 diluted with 75-125 ml of normal saline or dextrose 5%,
and infused for 20 min on days 1 and 3. Dexametasone, 8 mg i.v. on
days 1 and 3, and 4 mg i.v. on day 2, was used as prophylactic anti-
emetic treatment combined with metoclopramide at 20 mg on days
1-3. The treatment was administered in an out-patient setting every 3
weeks. Patients on medical therapy with luteinizing hormone-
releasing hormone analogs continued this treatment to maintain their
serum testosterone within castration level. Other hormonal agents
had to be discontinued for at least 1 month before treatment
initiation to overcome withdrawal responses. 
The toxicity of each cycle was recorded before the
administration of the next one. Dose modifications were made
according to the worst toxicity observed during the previous cycle.
A decrease of 5-FU, FA and Vinorelbine to 75% of total dose was
performed in the case of NCI Grade 3 or 4 stomatitis, neutropenia,
thrombocytopenia, diarrhea or other Grade 3 major organ drug-
related toxicity, after delaying the cycle until full recovery from
stomatitis or diarrhea and recovery of blood counts to: neutrophils
> 1.5 x 109/l and platelets > 100 x 109/l.
Radiotherapy was allowed when other parameters of disease
were documented, except for the treated side. In case of
concomitant radiotherapy, the dose of 5-FU and FA remained
unchanged, while Vinorelbine was reduced to a total dose of 20 mg.
Results
Thirty-four patients were enrolled between December 1996
and March 2000 and 30 were evaluable for analysis. The
patients’ characteristics are summarized in Table I. The
median age was 70 years, range 45 -77. The median time
from the progression on primary hormone treatment to the
start of chemotherapy was 15 months (range 2 - 120). 
A total of 127 treatment cycles (median 3, range 1-8 ) was
administered. Treatment was discontinued before
completing two cycles in four patients: one for sudden death
without cardiac anamnesis, one for rapid deterioration of
PS, one for duodenal perforation due to concomitant
NSAIDs and one for cumulative toxicity due to concomitant
radiotherapy and chemotherapy (protocol violation). In one
patient the treatment was completed for all eight planned
cycles. Ten cycles out of 127 (7.8 %) were delayed in six
patients for hematological toxicity; six patients required a
dose reduction in eleven cycles because of G3 neutropenia
(3), G3 anemia (2) and moderate asthenia (1). Thus, 116
cycles (91%) were administered at full dose.
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Table I. Patient characteristics at study onset.
No. of patients 30
Age, years 
median 70



































The most common toxicity was hematological with Grade
4 granulocytopenia observed at re-cycle of treatment in five
patients. Symptomatic anemia requiring transfusions was
reported in two cases. The worst grades of hematological
toxicity in patients are summarized in Table II. The other
toxicities were of low incidence and mild in severity (Table
II). No severe nausea or vomiting was reported. No
superficial phlebitis or deep venous thrombosis was
described and, in this case, the possible protective role of
the central-venous-catheter was considered. 
Response. Out of the 15 patients with measurable disease,
four partial responses (PR) (26.6%; 95% C.I., 28.3% to 65.7)
were reported, three in the lymph nodes and one in the lung.
In two patients with bone and soft tissue disease
involvement, bone localization was evaluated with CT and
bone scan that confirmed PR. In the remaining eleven
patients, four stable disease (SD) and seven progression of
disease (PD) were observed. Six out of 15 patients with only
bone disease had SD and nine PD. Disease stabilization was
obtained in ten patients out of the 30 evaluable cases (33%).
The median duration of response and stabilization was 4
months (range 2-6). The median time to progression (TTP)
and median overall survival time (OST) were calculated on
all 34 registered cases (intention-to-treat analysis) and were
of 10 (range 1 - 34+) and 42 weeks (range 1+ - 66+),
respectively. 
Six out of the 30 patients (20%) had a biological response
with a serum PSA decline of >50% or more and eihgt cases
(26.6%) presented PSA stabilization. Among four
responders, two PSA reductions ≥50% and two PSA
stabilizations were reported, while four PSA responses were
observed in ten patients with SD. The biological response
was correlated with clinical improvement in six patients. All
30 patients presented PS≥1 at baseline evaluation: PS
improved in four cases with PR and in ten cases with SD (14
patients, 47%) , while it was unchanged in the 16 remaining
patients. All 30 patients presented bone pain requiring
analgesics at the onset of chemotherapy: 14 achieved a
significant reduction of pain; in two cases pain remained
stable, but worsened in the remaining 14. Among the 15
patients with NSAIDs, five were able to stop analgesic
medications, five patients out of the ten treated with weak
opioids switched to NSAIDs and, of the five patients who
received strong opioids, four switched to weak opioids. 
Discussion
The aim of this study was to evaluate the efficacy of a
combination of Vinorelbine, 5-FU and FA, in patients with
HRPC. A regimen with a low subjective toxic burden
appeared attractive in elderly patients, preserving and, when
possible, improving their quality of life. Based on the
premise of an easy and manageable regimen for HPRC
patients, with the aim of controlling tumor-related symptoms
and increasing progression-free survival, we tested an
experimental regimen that we had used in breast cancer (29).
In detail, we had observed that Vinorelbine plus FA and 
5-FU, in advanced breast cancer, had considerable efficacy
(response rate 60% with CR 18%) with an excellent
subjective tolerability: the dose-limiting toxicity was Grade 
3-4 neutropenia recorded at nadir, with a very low incidence
of Grade 2 nausea, vomiting and alopecia.
The clinical experience related to prostate malignancy
indicates the difficulty in documenting responses to systemic
therapies according to traditional criteria, owing to the
preponderance of patients with only bone metastases (non-
measurable disease). Different criteria have to be
considered to evaluate the clinical response as a clinical
benefit index: namely amelioration of the PS, subjective
reduction of cancer pain and reduction of analgesic intake. 
The role of the PSA test in HRPC is unclear, even if it
remains a highly sensitive tumor marker for screening, for
monitoring loco-regional spread after medical or surgical
treatment, for evaluating residual disease or for early
detection of tumor relapse (30, 31). There are some data
supporting the evaluation of PSA values as a surrogate
response parameter, although it is known that tumor
progression may occur in a subset of patients even without
concomitant increased PSA levels (32). The results of our
study confirmed the role of chemotherapy as a palliative
treatment for HRPC. The overall data regarding median
TTP or median overall survival are similar to those obtained
by most mono- and poly-chemotherapy associations with the
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Table II. Toxicity data for FLN regimen (NCI-CTC Grade). Number of
patients: 30.
Grade
1 2 3 4
Toxic event No. No. No. No.
Leukocytes 2 4 6 2
Neutropenia 1 0 3 5
Anemia 1 6 2 0
Thrombocytopenia 1 0 0 0
Hepatic AST 3 0 0 0
Hepatic ALT 2 0 0 0
Total bilirubin 0 0 0 0
Nausea/Vomiting 8 3 0 0
Diarrhea 3 0 0 0
Constipation 9 3 0 0
Mucositis 3 2 0 0
Alopecia 1 0 0 0
Asthenia 9 3 1 0
advantages of good patient tolerance and mild and
reversible toxicity. Specifically, recent data on docetaxel
activity in HRPC showed a 45% and 48% reduction in PSA
levels in patients receiving docetaxel weekly and every 3
weeks, respectively. All these patients received high-dose
dexamethasone due to docetaxel premedication. Our
patients received a low dose of steroids.
Previous studies conducted with Vinorelbine, used as a
single agent or in combination, reported similar results in
terms of clinical impact and patient benefit. In our series,
no local reaction or superficial or deep venous thrombosis
was witnessed, thereby contributing to a better compliance
to the treatment plan. No paresthesias, constipation or
other neurological side-effects attributed to the vinca
alkaloids were registered. The amelioration of the PS in
symptomatic patients was detected in 14 (47%) patients. 
Our data, compared to the results regarding mitoxantrone
and prednisone described by Tannock et al. in a randomized
trial, showed a more consistent improvement in pain control
and/or a decrease in analgesia associated with improvements
in the PS, a minor duration of response, probably due to
unfavorable patient characteristics, but a similar overall
survival time (7, 33). 
In 46.6% of the patients, a significant reduction and
stabilization of the PSA were reported and, in six of these
patients, the PSA values were reduced by 50% or more
with respect to the baseline documentation. We observed a
correlation between the PSA measurements and clinical
outcome in the majority of patients in our series. The
decrease in serum PSA levels was not always consistent
with clinical response to treatment and in only six out of
14 cases showing clinical benefit was a biological
correlation found. This discordance had been observed in
other studies of patients with prostate cancer (17, 34-36).
Thus, the role of this marker remains unclear in this
population of patients. 
The manageable and predictable toxicity of the regimen
investigated here was associated with encouraging results
related to clinical benefit. We can conclude that
chemotherapy (FLN regimen) is a reasonable option in
patients with HRPC for its palliative role in cancer pain,
however, the optimal timing of its use has to be explored. 
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